Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
VKTX

VKTX - Viking Therapeutics Inc Stock Price, Fair Value and News

62.02USD-0.99 (-1.57%)Delayed as of 23 May 2024, 02:06 pm ET

Market Summary

VKTX
USD62.02-0.99
Delayedas of 23 May 2024, 02:06 pm
-1.57%

VKTX Alerts

  • 2 major insider sales recently.

VKTX Stock Price

View Fullscreen

VKTX RSI Chart

VKTX Valuation

Market Cap

6.9B

Price/Earnings (Trailing)

-74.14

Price/Free Cashflow

-126.63

VKTX Price/Sales (Trailing)

VKTX Profitability

Return on Equity

-10.04%

Return on Assets

-9.69%

Free Cashflow Yield

-0.79%

VKTX Fundamentals

VKTX Earnings

Earnings (TTM)

-93.7M

Earnings Growth (Yr)

-40.06%

Earnings Growth (Qtr)

-11.18%

Breaking Down VKTX Revenue

52 Week Range

10.6664.94
(Low)(High)

Last 7 days

-19.2%

Last 30 days

-1.3%

Last 90 days

76.7%

Trailing 12 Months

176.7%

How does VKTX drawdown profile look like?

VKTX Financial Health

Current Ratio

29.48

VKTX Investor Care

Shares Dilution (1Y)

40.73%

Diluted EPS (TTM)

-0.93

Tracking the Latest Insider Buys and Sells of Viking Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 03, 2024
zante greg
sold
-4,986,010
74.69
-66,756
chief financial officer
May 03, 2024
zante greg
acquired
166,285
4.85519
34,249
chief financial officer
May 01, 2024
mancini marianna
acquired
1,740,580
6.18486
281,425
chief operating officer
May 01, 2024
mancini marianna
sold
-22,136,500
78.6585
-281,425
chief operating officer
Mar 27, 2024
mancini marianna
acquired
-
-
31,667
chief operating officer
Mar 27, 2024
mancini marianna
sold (taxes)
-1,384,280
83.34
-16,610
chief operating officer
Mar 27, 2024
lian brian
acquired
-
-
221,667
president & ceo
Mar 27, 2024
lian brian
sold (taxes)
-12,830,000
83.34
-153,948
president & ceo
Mar 27, 2024
zante greg
acquired
-
-
31,667
chief financial officer
Mar 27, 2024
zante greg
sold (taxes)
-1,384,280
83.34
-16,610
chief financial officer

1–10 of 50

Which funds bought or sold VKTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-547,000
-
-%
May 17, 2024
Artal Group S.A.
new
-
20,816,800
20,816,800
0.53%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-0.9
21,943,200
28,461,200
0.01%
May 16, 2024
COMERICA BANK
added
28,154
7,500,480
7,506,510
0.03%
May 16, 2024
Tidal Investments LLC
new
-
2,373,310
2,373,310
0.04%
May 16, 2024
CASTLEARK MANAGEMENT LLC
new
-
4,566,500
4,566,500
0.19%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.2
5,413,870
7,118,010
0.01%
May 15, 2024
Dana Investment Advisors, Inc.
new
-
237,882
237,882
0.01%
May 15, 2024
GOLDMAN SACHS GROUP INC
reduced
-42.66
31,819,000
52,660,100
0.01%
May 15, 2024
OSTERWEIS CAPITAL MANAGEMENT INC
new
-
2,037,290
2,037,290
0.12%

1–10 of 35

Are Funds Buying or Selling VKTX?

Are funds buying VKTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VKTX
No. of Funds

Unveiling Viking Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
viking global investors lp
5.1%
5,145,112
SC 13G/A
Feb 13, 2024
vanguard group inc
5.38%
5,381,904
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.6%
7,605,867
SC 13G
Jan 24, 2024
state street corp
5.73%
5,732,990
SC 13G/A
Jan 12, 2024
millennium management llc
0.4%
403,556
SC 13G/A
Nov 02, 2023
viking global investors lp
5.9%
5,858,532
SC 13G
Apr 10, 2023
fmr llc
-
0
SC 13G
Mar 30, 2023
ligand pharmaceuticals inc
4.6%
3,616,077
SC 13D/A
Feb 14, 2023
arrowmark colorado holdings llc
0.02%
15,931
SC 13G/A

Recent SEC filings of Viking Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 22, 2024
S-8
Employee Benefits Plan
May 22, 2024
S-8 POS
Employee Benefits Plan
May 03, 2024
144
Notice of Insider Sale Intent
May 03, 2024
4
Insider Trading
May 02, 2024
4
Insider Trading
May 01, 2024
144
Notice of Insider Sale Intent
Apr 25, 2024
10-Q
Quarterly Report
Apr 24, 2024
8-K
Current Report
Apr 05, 2024
ARS
ARS
Apr 05, 2024
DEF 14A
DEF 14A

Peers (Alternatives to Viking Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Viking Therapeutics Inc News

Latest updates
Defense World9 hours ago
The Motley Fool17 May 202401:00 pm
StockNews.com02 May 202407:00 am
InvestorPlace26 Mar 202407:00 am

Viking Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets162.6%968368383401151169167182195211224238250257264271277284290294300
  Current Assets163.1%966367381399149167165180193211224238250256263271276284289294299
    Cash Equivalents252.3%19656.0037.0070.0018.0037.0029.0016.0012.0026.0011.009.0017.0029.004.0019.0015.008.0031.0019.0014.00
Liabilities67.5%34.0020.0014.0015.0017.0023.0015.0016.0013.009.0011.0013.0013.0012.0010.009.009.007.007.006.006.00
  Current Liabilities71.3%33.0019.0013.0013.0016.0022.0014.0015.0011.009.0011.0013.0013.0012.0010.009.009.007.006.006.005.00
Shareholder's Equity168.0%934348368386134145151165182202213225237244254262268277283288295
  Retained Earnings-7.2%-405-377-353-330-311-292-272-256-239-223-210-197-182-168-157-147-138-128-121-115-107
  Additional Paid-In Capital82.8%1,341734729725453445432430428426424423420413411410407406405404402
Shares Outstanding10.1%11010010010078.0078.0077.0077.0077.0077.0077.0076.0075.0073.0072.0072.0072.0072.00---
Float----94.00---196---417---470---535-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations65.2%-6,134-17,640-19,658-11,435-24,643-10,926-13,499-13,442-10,530-12,350-10,926-13,434-10,876-5,486-5,323-6,666-4,302-11,743-3,398-6,459-3,152
  Share Based Compensation95.6%7,9814,0804,4814,6203,5692,1561,9402,2202,3571,4331,5991,4911,5771,0431,4741,6481,6529768119221,034
Cashflow From Investing-1386.7%-459,79235,733-12,534-204,4832,1987,26026,89418,9801,61927,41013,6173,560-6,62730,269-9,6349,78011,152-11,06115,15410,979-7,609
Cashflow From Financing322260.1%606,037188-74.00267,0784,18410,74910.00-1,590-5,00647.00-2561,8985,19146437.0041633.0022973.00260325
  Buy Backs--------1,6745,121------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VKTX Income Statement

2024-03-31
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenues$ 0$ 0
Operating expenses:  
Research and development24,10311,008
General and administrative9,9709,529
Total operating expenses34,07320,537
Loss from operations(34,073)(20,537)
Other income (expense):  
Amortization of financing costs(28)(28)
Interest income, net6,7451,034
Total other income, net6,7171,006
Net loss(27,356)(19,531)
Other comprehensive loss, net of tax:  
Unrealized gain (loss) on securities(1,125)501
Foreign currency translation loss(85)(17)
Comprehensive loss$ (28,566)$ (19,047)
Basic net loss per common share$ (0.26)$ (0.25)
Diluted net loss per common share$ (0.26)$ (0.25)
Weighted-average shares used to compute basic net loss per share103,457,30578,351,826
Weighted-average shares used to compute diluted net loss per share103,457,30578,351,826

VKTX Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 195,579$ 55,516
Short-term investments – available for sale767,397306,563
Prepaid clinical trial and preclinical study costs2,7162,624
Prepaid expenses and other current assets6432,522
Total current assets966,335367,225
Right-of-use assets1,0521,126
Deferred financing costs98106
Deposits3333
Total assets967,518368,490
Current liabilities:  
Accounts payable5,2257,512
Other accrued liabilities27,22011,299
Lease liability, current329324
Total current liabilities32,77419,135
Lease liability, net of current portion852936
Total long-term liabilities852936
Total liabilities33,62620,071
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 110,228,869 shares issued and outstanding at March 31, 2024 and 100,113,770 shares issued and outstanding at December 31, 202311
Treasury stock at cost, no shares at March 31, 2024 and 2,193,251 shares at December 31, 20230(6,795)
Additional paid-in capital1,340,789733,546
Accumulated deficit(405,299)(377,944)
Accumulated other comprehensive loss(1,599)(389)
Total stockholders’ equity933,892348,419
Total liabilities and stockholders’ equity$ 967,518$ 368,490
VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
 CEO
 WEBSITEvikingtherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES22

Viking Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Viking Therapeutics Inc? What does VKTX stand for in stocks?

VKTX is the stock ticker symbol of Viking Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viking Therapeutics Inc (VKTX)?

As of Wed May 22 2024, market cap of Viking Therapeutics Inc is 6.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VKTX stock?

You can check VKTX's fair value in chart for subscribers.

What is the fair value of VKTX stock?

You can check VKTX's fair value in chart for subscribers. The fair value of Viking Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viking Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VKTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viking Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VKTX is over valued or under valued. Whether Viking Therapeutics Inc is cheap or expensive depends on the assumptions which impact Viking Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VKTX.